meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - all population
1
mUC - M - PDL1 positive
1
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">avelumab based treatment</span>
<span style="margin-left: 3em;">avelumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">non active control</span>
<span style="margin-left: 1em;">BSC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (2)
progression or deaths (PFS) (2)
objective responses (ORR) (2)
deaths (OS) (extension) (2)
DCR (2)
PFS (extension) (2)
TRAE leading to death (grade 5) (2)
AE (any grade) (1)
TRAE (any grade) (1)
SAE (any grade) (1)
AE leading to treatment discontinuation (any grade) (1)
TRAE (grade 3-4) (1)
AE (grade 3-4) (1)
TRAE leading to discontinuation (any grade) (1)
AE leading to death (grade 5) (1)
STRAE (any grade) (1)
Chills TRAE (grade 3-4) (1)
Diabetes TRAE (grade 3-4) (1)
Pancreatitis TRAE (grade 3-4) (1)
Nephritis TRAE (grade 3-4) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Colitis TRAE (grade 3-4) (1)
Uveitis TRAE (grade 3-4) (1)
Myositis TRAE (grade 3-4) (1)
Infusion-related reactions TRAE (grade 3-4) (1)
Arthritis TRAE (grade 3-4) (1)
Guillain-Barré syndrome TRAE (grade 3-4) (1)
Arthralgia TRAE (grade 3-4) (1)
Hypothyroidism TRAE (grade 3-4) (1)
Hyperthyroidism TRAE (grade 3-4) (1)
Thyroiditis TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Vitiligo TRAE (grade 3-4) (1)
Asthenia TRAE (grade 3-4) (1)
Dry skin TRAE (grade 3-4) (1)
Pyrexia TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Increased lipase level TRAE (grade 3-4) (1)
Adrenal insufficiency TRAE (grade 3-4) (1)
Diarrhoea AE (grade 3-4) (1)
Rash AE (grade 3-4) (1)
Pyrexia AE (grade 3-4) (1)
Pruritus AE (grade 3-4) (1)
Nausea AE (grade 3-4) (1)
Vomiting AE (grade 3-4) (1)
Constipation AE (grade 3-4) (1)
Fatigue AE (grade 3-4) (1)
Asthenia AE (grade 3-4) (1)
Decreased appetite AE (grade 3-4) (1)
Hypothyroidism AE (grade 3-4) (1)
Arthralgia AE (grade 3-4) (1)
Anaemia AE (grade 3-4) (1)
Cough AE (grade 3-4) (1)
Infusion-related reaction AE (grade 3-4) (1)
hepatitis (Autoimmune) AE (grade 3-4) (1)
Back pain AE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Evidence network for deaths_(OS)
2
JAVELIN Bladder 100 (all population), 2020 JAVELIN Bladder 100 (PDL1>25%), 2020
BSC
avelumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
BSC
avelumab alone
BSC
---
NA
avelumab alone
NA
---
pathologies: 289,188,189 - treatments: 417
result logic
×
Study list
